Biological Therapies for Urate Lowering and Inflammation Control in Gout Management

Abstract: Gout remains the most prevalent inflammatory arthritis worldwide, driven by hyperuricemia and monosodium urate crystal-induced inflammation. Conventional therapies manage most patients effectively, but refractory disease and contraindications in special populations create unmet clinical needs. This gap is particularly evident among patients with advanced chronic kidney disease or organ transplants. Biologic therapies targeting key pathophysiologic mechanisms have emerged as specialized options for these difficult-to-treat cases. Pegloticase achieves sustained urate reduction in refractory gout. Concomitant immunomodulatory therapy using methotrexate or mycophenolate substantially improves response rates by mitigating antidrug antibody formation. Anti-inflammatory biologics targeting the interleukin-1 (IL-1) pathway underwent a prolonged clinical translation process. Anakinra accumulated extensive off-label evidence over two decades without formal approval, while rilonacept faced regulatory rejection in 2012 despite demonstrating efficacy. Canakinumab received Food and Drug Administration (FDA) approval in August 2023 after its initial rejection in 2011, becoming the first biologic formally indicated for gout in the United States. NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome inhibitors represent a recent area of investigation. OLT1177 has advanced through clinical development after incorporating safety lessons from the hepatotoxicity experience associated with MCC950. Diverse pipeline compounds further reflect active research in this therapeutic class. Biologics function as rescue options for patients with inadequate responses to conventional treatment rather than as first-line alternatives. Remaining challenges include immunogenicity management, treatment costs that limit accessibility, and incomplete long-term safety characterization. Future progress depends on refining patient selection through predictive biomarkers and ensuring appropriate access for patients most likely to benefit from these advances. Keywords: gout, biological products, urate oxidase, interleukin-1, NLR family, pyrin domain-containing 3 protein, hyperuricemia